Ocugen Provides Business Update with Second Quarter 2026 Financial Results
Ocugen reported Q2 2026 financial results highlighted by FDA clearance to initiate the Phase 3 ArMaDa3 trial for OCU410 in geographic atrophy and receipt of Regenerative Medicine Advanced Therapy (RMAT) designation. The company strengthened its balance sheet by closing a $130 million convertible senior notes offering, extending its cash runway into 2028 and using $32.7 million of proceeds to fully retire a high-interest loan from Avenue Capital.
Key figures
- Revenue
- 1488000
- Notes due
- 2034
- Cash runway
- into 2028
- Cash position
- $100.4 million
- Notes interest rate
- 6.75%
- Deal value milestones
- $255 million
- Offering proceeds net
- $112.5 million
- Retired debt interest
- 12.25%
- Trial subjects OCU400
- 140
- Trial subjects OCU410 ST
- 63
- Trial subjects OCU410 planned
- 237
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.